Epidemiology of hospitalizations with hallucinogen use disorder: a 17-year U.S. National study
This long-term study (17 years) assessed time-trends and outcomes of hallucinogen use disorder per 100,000 in the US. Hallucinogen use disorders hospitalizations were common and increased from 1998-2014. Modifiable patient and hospital factors can reduce this burden.
Abstract
Objective
To assess time-trends and outcomes of hallucinogen use disorder hospitalizations.
Methods
The U.S. National Inpatient Sample (NIS) data from 1998 to 2014 were used. People hospitalized with hallucinogen use disorder as primary or secondary diagnosis were assessed. Rates were calculated per 100,000 NIS claims. Multivariable-adjusted logistic regression analyses assessed the association of patient and hospital characteristics with outcomes.
Results
The national U.S. rates per 100,000 total NIS claims for hallucinogen use disorder hospitalizations increased from 1998-2000 to 2013-2014 and outcomes worsened over time:1 hospitalizations, from 22.8 to 40.4 (1.8-fold);2 in-hospital mortality rate, from 0.3 to 0.6 (2.3-fold); and3 non-home discharge, from 4.2 to 6.3 (1.5-fold), respectively. Various patient and hospital characteristics were associated with worse healthcare utilization outcomes and in-hospital mortality.
Conclusions
Hallucinogen use disorder hospitalizations were common and increased from 1998 to 2014 in the U.S. interventions targeting modifiable patient and hospital factors can potentially reduce this burden.
Research Summary of 'Epidemiology of hospitalizations with hallucinogen use disorder: a 17-year U.S. National study'
Introduction
Hallucinogens produce marked alterations in thought, perception and mood and are commonly grouped into serotonergic (tryptamine- and phenethylamine-like), N-methyl-D-aspartate (NMDA) antagonist, and other classes. Although hallucinogen use disorder is relatively uncommon compared with alcohol or opioid disorders, it nevertheless contributes to inpatient healthcare burden; in 2012 hallucinogen use disorders ranked among the top five substance-related diagnoses for adult inpatient stays in the USA. Previous prevalence estimates cited by the authors put past-year hallucinogen use disorder at about 0.06% and lifetime prevalence at about 0.6%, but national data on hospitalisation trends and inpatient outcomes for this disorder have been lacking. Singh set out to describe national time-trends in hospitalisations with hallucinogen use disorder in the USA over a 17-year period, to quantify associated healthcare utilisation and in-hospital mortality, and to identify patient and hospital factors associated with worse outcomes. The study aimed to fill the gap in epidemiological knowledge about the hospital burden of hallucinogen use disorder and to highlight potential targets for interventions or policy measures.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- APA Citation
Singh, J. A. (2021). Epidemiology of hospitalizations with hallucinogen use disorder: a 17-year U.S. National study. Journal of Addictive Diseases, 39(4), 545-549. https://doi.org/10.1080/10550887.2021.1907503
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.